Benign testicular tumors in children with congenital adrenal hyperplasia.
The association between testicular tumors/nodules and congenital adrenal hyperplasia (CAH) has been previously reported. From 1960 to 1989, three patients (13 to 18 years old) with long-standing CAH developed testicular masses. Two patients with 21-hydroxylase deficiency were diagnosed in the neonatal period while one other with 11-hydroxylase deficiency was diagnosed at 3 years of age when he presented with sexual precocity. In all three patients, medical compliance was poor. The testicular masses were bilateral in two patients and unilateral in one, measured 1 to 2 cm, and occupied only the upper half of the testicle. Testicular biopsy specimens were obtained after at least 6 months of evidence of compliance with the adrenocorticotrophic hormone (ACTH) suppressive medication and failure of the nodules to regress. On gross examination the masses appeared to be firm yellow brown nodules. Light microscopy showed interlacing strands, cords, and rests of cells resembling interstitial (Leydig) cells but with no Reinke crystalloids. Electronmicroscopy in all patients showed variable amounts of both smooth and rough endoplasmic reticulum, the later with occasional dilated cisternae. Follow-up ranged from 6 months to 6 years. No further surgical treatment has been necessary. There has been no evidence of recurrence, distant metastases, or secondary malignancies during the time of follow-up. These findings suggest that testicular tumors may develop from chronic excessive ACTH stimulation of a putative pluripotential testicular cell, a Leydig cell, or an adrenal cortical rest. Unlike other testicular tumors these do not require orchiectomy as the initial form of therapy.
Srikanth
M S
MS
Division of Pediatric Surgery, Children's Hospital of Los Angeles, CA.
West
B R
BR
Ishitani
M
M
Isaacs
H
H
Applebaum
H
H
Costin
G
G
D000293:Adolescent; D000312:Adrenal Hyperplasia, Congenital / Q000150:complications* / Q000188:drug therapy / Q000201:enzymology; D000324:Adrenocorticotropic Hormone / Q000008:administration & dosage*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007984:Leydig Cell Tumor / Q000209:etiology* / Q000473:pathology / Q000601:surgery / Q000648:ultrastructure; D007985:Leydig Cells / Q000473:pathology* / Q000648:ultrastructure; D008297:Male; D008854:Microscopy, Electron; D009367:Neoplasm Staging; D009919:Orchiectomy; D010349:Patient Compliance; D013736:Testicular Neoplasms / Q000209:etiology* / Q000473:pathology / Q000601:surgery / Q000648:ultrastructure; D013737:Testis / Q000473:pathology* / Q000648:ultrastructure
D000324:Adrenocorticotropic Hormone